Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Enterprise Value: 2013-2025

Historic Enterprise Value for Coherus Oncology (CHRS) over the last 12 years, with Sep 2025 value amounting to -$1.1 million.

  • Coherus Oncology's Enterprise Value rose 92.65% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$447.1 million, marking a year-over-year increase of 18.87%. This contributed to the annual value of -$19.9 million for FY2024, which is 107.85% down from last year.
  • According to the latest figures from Q3 2025, Coherus Oncology's Enterprise Value is -$1.1 million, which was up 99.22% from -$134.9 million recorded in Q2 2025.
  • Coherus Oncology's Enterprise Value's 5-year high stood at $808.3 million during Q4 2021, with a 5-year trough of -$134.9 million in Q2 2025.
  • Moreover, its 3-year median value for Enterprise Value was $9.6 million (2024), whereas its average is $84.6 million.
  • Over the last 5 years, Coherus Oncology's Enterprise Value had its largest YoY gain of 92.65% in 2025, and its largest YoY loss of 1,170.17% in 2025.
  • Coherus Oncology's Enterprise Value (Quarterly) stood at $808.3 million in 2021, then crashed by 47.50% to $424.3 million in 2022, then tumbled by 40.35% to $253.1 million in 2023, then slumped by 107.85% to -$19.9 million in 2024, then soared by 92.65% to -$1.1 million in 2025.
  • Its last three reported values are -$1.1 million in Q3 2025, -$134.9 million for Q2 2025, and $11.1 million during Q1 2025.